$A breaking out of a massive 5-year base. As AI adoption accelerates across drug discovery and life sciences, the infrastructure providers behind the research could see real upside.
Strong free cash flow, improving EPS trajectory. Classic setup โ the bigger the base, the higher the breakout potential. Worth watching if you're tracking AI's second-order plays beyond the usual suspects.
Strong free cash flow, improving EPS trajectory. Classic setup โ the bigger the base, the higher the breakout potential. Worth watching if you're tracking AI's second-order plays beyond the usual suspects.